HBM Healthcare Investments to Sell Major Stake in Swixx Biopharma

HBM Healthcare Investments AG has announced it will sell a majority stake in Swixx Biopharma. The transaction involves SK Capital Partners acquiring the stake, valuing Swixx Biopharma at over EUR 1.5 billion. This deal also includes other shareholders such as the founders and Mérieux Equity Partners. HBM will retain a minority stake and expects the completion by mid-2026.

The transaction has led to a revaluation of HBM's investment, increasing the net asset value per share by approximately CHF 13.50. HBM, which has invested EUR 26 million in Swixx Biopharma since 2017, anticipates a cash inflow exceeding the reported book value. The investment has so far yielded a capital gain of about CHF 300 million.

Despite selling a majority stake, HBM will maintain its 25.1% ownership in Swixx Healthcare. Dr. Andreas Wicki, CEO of HBM, expressed enthusiasm for ongoing collaborations with Swixx's management and partners.